Skip to main content


Paul Knoebl
A.Univ.Prof. Paul Knoebl, MD

Department of Medicine I (Division of Hematology and Hemostaseology)
Position: Associate Professor

T +43 1 40400 49560


Anticoagulants; Critical Illness; Hemophilia A; Protein C; Purpura Fulminans; Rare Diseases; Sepsis; Thrombotic Microangiopathies; von Willebrand Factor

Research interests

  • Immune mediated coagulation disorders (incl. acquired hemophilia, antiphospholipid antibodies, immune thrombocytopenia)
  • Thrombotic microangiopathy (incl. thrombotic thrombocytopenic purpura, Upshaw.Schulman Syndrome, hemolytic uremic syndrome, etc.)
  • Critical illness coagulopathy (incl. purpura fulminans, sepsis, etc.)
  • rare bleeding disorders

Techniques, methods & infrastructure

  • Anti-ADAMTS13 antibody ELISA


Selected publications

  1. Tiede, A. et al., 2014. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood, 125(7), pp.1091-1097. Available at:
  2. Knobl, P., 2014. Inherited and Acquired Thrombotic Thrombocytopenic Purpura (TTP) in Adults. Seminars in Thrombosis and Hemostasis, 40(04), pp.493-502. Available at:
  3. KNOEBL, P. et al., 2012. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Journal of Thrombosis and Haemostasis, 10(4), pp.622-631. Available at:
  4. Knoebl, P. Drugs Today (Barc). 2008 Jun;44(6):429-41, Human protein C concentrates for replacement therapy in congenital and acquired protein C deficiency.
  5. Knobl, P., 2015. NET untangled in TMA? Journal of Thrombosis and Haemostasis, 13(5), pp.729-731. Available at: